Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / MediciNova
Company

MediciNova

Tracked across 1 events · 7 articles · First seen Jan 29, 2026 · Last active Jan 29, 2026

Sentiment
70
Attention
4
Events
1
Relationships
3
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Business
MediciNova's MN-166 ALS Study Reaches 50% Enrollment
MediciNova announced significant progress in its SEANOBI study for amyotrophic lateral sclerosis (ALS) treatment, with 100 patients enrolled. This milestone, along with the ongoing COMBAT-ALS study, is expected to support regulatory discussions for Ibudilast.
Jan 29, 2026 · 7 articles
Relationships (3)
United States===National Institute of Neurological Disorders and Stroke funder of ↔ MediciNova United States===National Institute of Neurological Disorders and Stroke (NINDS)
Yuichi Iwaki CEO of ↔ MediciNova Yuichi Iwaki is the President and CEO of MediciNova, leading its strategic direc
European Union===European Medicines Agency regulator of ↔ MediciNova European Union===European Medicines Agency (EMA) regulates MediciNova's drug dev
NEWSDESK
Track MediciNova live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.